CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.
October 25th 2018
A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.
October 25th 2018
Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.
October 8th 2018
The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.
October 1st 2018
The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.
September 20th 2018
September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:
September 17th 2018
A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.
September 13th 2018
Injectable forms of medication may benefit patients with blood cancers.
September 10th 2018
Previously, there were concerns that older patients would not be able to handle the toxicities of the procedure, or that their stem cells, which are older, would not work as well. But that proved to not be the case.
August 23rd 2018
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor (PI).
August 17th 2018
See what CURE readers have to say about our previous issues.
August 16th 2018
In this week’s episode of CURE Talks Cancer, we spoke with Ethan Hawes about his experience as a 22-year-old diagnosed with multiple myeloma, and his advice for others going through a similar journey.
August 14th 2018
A patient's bone health history may offer clues into their myeloma outcomes, according to a recent study.
August 9th 2018
Understanding these outcomes is important in planning treatments and mitigating the possibility of patients stopping their treatment.
July 28th 2018
Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.
July 24th 2018
Here is what one expert says about the right time to start treating relapsed multiple myeloma.
July 23rd 2018
This hike marks the fifth continent to be visited by a Moving Mountains for Multiple Myeloma team
July 9th 2018
Five leading cancer organizations came together to establish four steps that patients of all malignancies can turn to as they navigate their experience.
July 5th 2018
We spoke with two members of the Moving Mountains for Multiple Myeloma team.
June 20th 2018
MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds
June 19th 2018
Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.
June 12th 2018
The Food and Drug Administration (FDA) approved the supplemental New Drug Application to add to the U.S. Prescribing Information for Kyprolis (carfilzomib) for the treatment of patients with relapsed or refractory multiple myeloma.
June 8th 2018
Cancer affects many aspects of a person’s life, such as the overall quality of their day-to-day living, but what if a person didn’t have the full-blown disease already? Could a precursor or asymptomatic stage of the disease still burden them?
June 7th 2018
A two-drug regimen improved outcomes for patients with myeloma when given before a stem cell transplant.
June 6th 2018
Researchers are considering whether some smoldering myelomas warrant treatment and which regimens are best.
May 31st 2018
When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D.
May 30th 2018
A lack of vitamin D can have major impacts on myeloma treatment outomes.
May 19th 2018
Four oncology nurses were recognized during the inaugural event for their efforts to prioritize the health of patients’ bone health during treatment.
May 19th 2018
It takes a lot to call something a revolution in medicine ... The most important, of course, is its impact on people’s lives — particularly, a cure for illness or a major extension of life. A revolution also implies a sweeping cataclysmic change, one that is disruptive and boldly states that things will no longer be the same.